Non-steroidal anti-inflammatory drugs (NSAIDs) such as sulindac are promising chemoprevention agents against colon cancer, but their weak potency and side effects limit their use for both chemoprevention and chemotherapy. Here, we evaluated the effect of a new sulindac derivative, phospho-sulindac or OXT-922, on the growth of human cancer cell lines and its mechanism of action.
INTRODUCTION
Substantive epidemiological, in vitro and animal studies indicate that non-steroidal anti-inflammatory drugs such as aspirin, sulindac, and piroxicam have anti-tumorigenic activities against colorectal cancer.
NSAIDs inhibit cell cycle progression and cell proliferation and induce apoptosis in various cancer cell lines; several underlying molecular mechanisms have been suggested [1] . Inhibition of cyclooxygenase COX activity by NSAIDs, which leads to reduced prostaglandin synthesis, is considered important for their anti-tumorigenic activity [2] . On the other hand, an extensive array of non-COX targets of NSAIDs relevant to their anticancer properties has been identified. For example, NSAIDs also inhibit the growth of cancer cells expressing no COX-1/COX-2, and this effect might depend on NF-?B signaling inhibition, oxidative stress or reduced polyamine synthesis [3] [4] [5] .
Among the nearly 50 approved NSAIDs, aspirin and sulindac are probably the best studied.
Interventional clinical trials have demonstrated the cancer preventive effect of both, but neither had an effect strong enough to be clinically useful [6] [7] [8] [9] . As for any agent, besides efficacy, the safety of NSAIDs is another relevant consideration. NSAIDs, even though widely used, do carry significant toxicity, primarily gastrointestinal and renal [10] [11] . Such toxicity is expected to be more pronounced if they are to be used on a long-term basis for cancer prevention. Several attempts have been made to overcome the limitations of conventional NSAIDs, mainly those concerning their efficacy and safety. Some of these efforts include the chemical modification of the NSAID molecule in the hopes of generating pharmacologically superior derivatives. Two examples are the nitric oxide donating NSAIDs [12] and a modified sulindac [13] . These and other studies suggest that modifying the NSAIDs molecule may lead to useful new compounds.
In the present study, we evaluated the growth inhibitory effect of OXT-922, the novel sulindac derivative shown in Fig. 1 . We found that the growth inhibitory effect of OXT-922 in cancer cells was largely mediated by a) elevated levels of reactive oxygen species (ROS), which, in turn, activated relevant cell signaling, leading to apoptosis, and b) enhanced spermidine/spermine N 1 -acetyltransferase (SSAT) were grown in media recommended by American Type Culture Collection.
MATERIALS AND METHODS

Reagents and cell culture
Cell kinetic assays
Cells were seeded at a density of 5x10 4 cells/cm 2 and allowed to attach for 24 h, when various treatments were applied. 
Determination of ROS
We determined ROS levels with confocal microscopy and flow cytometry. 
Determination of mitochondrial membrane potential
The mitochondrial membrane potential was determined by flow cytometry using the 5,5,6,6-tetrachloro- 
Western blotting
After each treatment, cells were lysed on ice with 1% Triton X-100 lysis buffer with 2.5 mM 4-nitrophenylphosphate, 1% SDS and 0.25% sodium deoxycholate for 30 min. For each sample, 30 ?g of cell lysate were loaded onto SDS-electrophoresis gel and transferred onto a nitrocellulose membrane.
The membrane was then immunoblotted with primary antibodies followed by secondary antibodies conjugated with horseradish peroxidase (HRP) from Santa Cruz Biotechnology. Enhanced chemiluminescence (ECL) was used to visualize the bands on X-ray film.
Electrophoretic mobility shift assay (EMSA)
After the indicated treatment, cell nuclear fractions were isolated from 3x10 6 cells using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Scientific). The NF-?B activity was detected by using LightShift chemiluminescent EMSA kit (Thermo Scientific) according to the manufacturers instructions.
Briefly, the nuclear extracts were incubated with biotin-labeled DNA probes at 37 o C for 20 min, then loaded onto the polyacrylamide gel and transferred to a nylon membrane. The membrane was exposed to UV-light for 10 min for cross-linking of the transferred DNA, then incubated with stabilized streptavidinhorseradish peroxide conjugate in blocking buffer for 15 min and covered with substrate working solution, followed by exposure to X-ray film.
PGE2 assay
PGE 2 levels in culture media were determined using the kit from Cayman Chemical according to the manufacturers instruction. 
RESULTS
OXT-922 inhibits the growth of various human cancer cell lines: A strong cytokinetic effect
The growth inhibitory effect of OXT-922 was evaluated by the MTT assay in human cancer cell lines. As shown in Table 1 p53 (Fig. 2D ). Taken together, these changes provide at least a partial explanation of the cell cycle effect of OXT-922.
OXT-922 enhances ROS levels in colon cancer cells
ROS play a critical role in the mechanism of action of some anticancer compounds, including paclitaxel, arsenic trioxide and NO-aspirin [16] [17] [18] [19] . Therefore, we determined the ROS levels in HT (Fig. 3E, right panel) . The levels of ONOO -were also elevated 128% in SW480 cells (Fig. 3E, left panel) . Elevation of all these ROS levels was also observed in HT-29 cells in response to OXT-922 (Fig. S1 ).
OXT-922 induces redox-dependent apoptosis
ROS accumulation is critical for the induction of apoptosis by many anticancer agents [16, 22] . As the O 2 ·-levels in mitochondria were markedly enhanced by OXT-922, we first tested for the loss of mitochondrial membrane potential, which is indicative of apoptosis [23] [24] . To this end, we used the unique fluorescent cationic dye, JC-1, which exhibits potential-dependent accumulation in mitochondria and forms red fluorescent J-aggregates [25] . As shown in suppressed the expression levels of phosphorylated and total Akt, which is critical for cell proliferation and survival [27] .
Oxidative stress can modulate cell survival through multiple mechanisms [28] . However, cell death can also lead to ROS enrichment [29] . To distinguish the causality between OXT-922-induced ROS production and apoptosis, we evaluated the effect of antioxidants on OXT-922-induced apoptosis. The
MTT assay showed that OXT-922 reduced cell viability in a concentration-dependent manner, and that this effect was effectively blocked by the antioxidants NAC, Tempol and Trolox [30] [31] (Fig. 4C) . NAC pretreatment also greatly blocked OXT-922-induced caspase-3 cleavage (Fig. 4D) , and protected cells from OXT-922 induced apoptosis ( Fig. 2A) , indicating that oxidative stress is a major player in the induction of apoptosis by OXT-922.
The effect of OXT-922 on MAPK, Trx, NF-кB and COX signaling pathways in colon cancer cells
Prior work has demonstrated the extensive effects of NSAIDs on cell signaling pathways including
MAPKs, NF-?B and Trx [32] [33] [34] . Thus, we explored whether OXT-922 affected these signaling pathways.
The levels of phosphorylated p38, JNK and ERK were not significantly affected by OXT-922 (data not shown). In contrast, the activation of NF-?B was largely inhibited by OXT-922, as revealed by the electrophoretic mobility shift assay (EMSA) shown in Figure 4E . Certain anticancer agents modulate NF-?B signaling through thioredoxin oxidation and activation of apoptosis signal-regulating kinase-1 (ASK1) [17, 35] . However, OXT-922 did not alter the oxidation level of Trx-1 neither did it reduce the physical association between ASK1 and Trx-1 (Fig. S2) . Instead, it directly downregulated the Trx-1 protein level ( Fig. 4F and Fig. S3 ). Finally, OXT-922 suppressed the expression of COX-1, notably at its IC 50 concentration and above, but had no effect on COX-2 expression over the same range of concentrations (Fig. 4G) . OXT-922, however, suppressed both the baseline and stimulated (by melittin) production of PGE 2 by HT-29 cells; the latter effect was pronounced reaching 86% (Fig. 4H) .
The effect of OXT-922 on polyamines; synergy with DFMO
It is reported that the growth inhibitory effect of sulindac on colon cancer cells is due, in part, to its ability to change polyamine metabolism [5] . The polyamines (putrescine, spermidine, and spermine) are abundant polycations, which are often elevated in neoplastic cells and affect numerous processes in carcinogenesis. Polyamine levels are tightly regulated by the biosynthetic enzyme ornithine decarboxylase [36] and the catabolic enzyme SSAT [37] . Sulindac enhances SSAT activity by increasing its transcription leading to suppressed polyamine content of cells [5] . We, therefore, evaluated whether (Fig. S4 ).
Given the clinically important effect of the combination of sulindac with DFMO, the most widely studied inhibitor of polyamine synthesis, on the prevention of colon cancer [38] , we evaluate whether OXT-922 synergizes with DFMO to inhibit colon cancer cell growth. The isobolograms depicted in A key finding of our study is that OXT-922 is able to significantly induce ROS production in colon cancer cells and that this effect is primarily responsible for the induction of apoptosis. Prior work has revealed that sulindac induces ROS production in cancer cells [39] [40] [41] . However, this effect is relatively Prior work by us has demonstrated that derivatives of NSAIDs modulate signaling pathways including MAPKs, COX, the Trx system and NF-?B [17, 33, 43] . Our current results show that OXT-922 exerts no effect on MAPK signaling, and suppresses NF-?B activity without Trx-1 oxidation. Interestingly, OXT-922 directly downregulates the expression of Trx-1. Considering the importance of Trx-1 in cancer development [44] [45] , the downregulation of Trx-1 by OXT-922 may contribute to its anti-cancer activity, a potential mechanism that deserves further study. OXT-922 had a rather unusual effect on the COX isozymes, in that it suppressed the expression of COX-1 while not affecting that of COX-2. The production of PGE 2 , the dominant PG produced by HT-29 cells, was markedly suppressed by OXT-922, especially following stimulation by melittin [3] . Of note the combination of OXT-922 with conventional sulindac had no additive effect, indicating perhaps maximal inhibition by either compound.
OXT-922 has a significant effect on the polyamine pathway, suppressing the levels of all three members (putrescine, spermidine, and spermine) that were assayed. This effect is partly due to its ability to stimulate the activity of SSAT, the enzyme that acetylates spermine and spermidine and exports them form the cell. An important finding was the synergy between OXT-922 and DFMO, which was due mainly to a marked enhancement of apoptotic cell death and to a lesser extent to inhibition of proliferation.
Taken together, our findings indicate that OXT-922, a derivative of sulindac belonging to the broader pharmacological category of modified NSAIDs, displays properties that are relevant to the control of cancer. Of particular interest are: a) its cell signaling mechanism involving two pathways that bear heavily on the fate of the cancer cell, and b) its ability to synergize with DFMO. OXT-922 is a promising novel agent worthy of further probing for its anticancer properties.
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